Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.
Garcovich, S., Ruggeri, A., D'Agostino, M., Ardito, F., De Simone, C., Delogu, G., Fadda, G., Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study, <<JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY>>, 2012; 26 (12): 1572-1576. [doi:10.1111/j.1468-3083.2011.04220.x] [http://hdl.handle.net/10807/40734]
Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study
Garcovich, Simone;Ruggeri, Alberto;D'Agostino, Magda;Ardito, Fausta;De Simone, Clara;Delogu, Giovanni;
2012
Abstract
Psoriasis patients who are treated with tumour necrosis factor (TNF)-alpha antagonists are at increased risk of reactivation of latent tuberculosis infection (LTBI) and should be adequately screened and monitored during active treatment.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
